{"prompt": "['SAR439774 (formerly ALN-AT3SC) (fitusiran)', 'Clinical Study Protocol ALN-AT3SC-003', '(Sanofi Genzyme EFC14768)', '27 Jun 2018', 'Patients who discontinue treatment during the study will be encouraged to continue recording', 'bleeding episode data.', 'Sensitivity analyses will be performed to evaluate the impact of missing data under different', 'missing data mechanisms and details will be specified in the statistical analysis plan.', '8.2.5.2.', 'Secondary Enppoints', 'The bleeding episodes in the treatment period (Day 1 to Day 246), spontaneous bleeding', 'episodes in the efficacy period, joint bleeding episodes in the efficacy period, and bleeding', 'episodes in the onset period will be analyzed using the same method as primary analysis of ABR.', 'Summary statistics, including the median and interquartile range for annualized rates of these', 'endpoints will be reported.', 'The change from baseline in physical health score and total score of Haem-A-QOL will be', 'analyzed using an analysis of covariance (ANCOVA) model with fixed effects of treatment arm,', 'baseline Haem-A-QOL physical health score and total score, and the number of bleeding', 'episodes in the 6 months prior to study entry (10 VS >10) as covariates. Domain scores for', 'Haem-A-QOL and their changes from baseline will be summarized descriptively by scheduled', 'visit.', '8.2.5.3.', 'Exploratory Enppoints', 'Details of the analyses for the exploratory endpoints will be described in the SAP.', '8.2.6.', 'Pharmacodynamic Analysis', 'AT and thrombin levels will be summarized descriptively by scheduled visit. Mixed models', 'repeated measures analyses may be performed as deemed appropriate. Correlation between AT', 'and thrombin levels may be explored.', '8.2.7.', 'Pharmacokinetic Analysis', 'Pharmacokinetic analyses will be conducted using a population PK approach on patients in the', 'fitusiran arm. The details of the analysis will be presented in a separate population PK analysis', 'plan.', 'In addition to performing population PK analyses, the following PK parameters will be included', 'in an analysis of East Asian patients in the fitusiran arm at East Asian sites: maximum plasma', 'concentration (Cmax), time to maximum plasma concentration (tmax), elimination half-life', 'area under the concentration-time curve (AUC), apparent clearance (CL/F), and apparent volume', 'of distribution (V/F); these parameters will be estimated during the fitusiran treatment period', 'using non-compartmental analysis. Other parameters may be calculated, if deemed necessary.', '8.2.8.', 'Safety Analyses', 'Extent of exposure will be summarized. Safety will be based on all AEs having onset (start or', 'worsening in severity) within the study and on the Safety Analysis Set. Incidence of AEs, AEs', 'by maximum severity, AEs by relationship to study medication, SAEs and AEs leading to', 'discontinuation of treatment will be presented.', 'Property of the Sanofi Group - strictly confidential', '69']['SAR439774 (formerly ALN-AT3SC) (fitusiran)', 'Clinical Study Protocol ALN-AT3SC-003', '(Sanofi Genzyme EFC14768)', '27 Jun 2018', 'Descriptive statistics will be provided for clinical laboratory data, ECG and vital signs.', 'Laboratory shift tables from baseline to worst post-baseline values may be presented.', 'Other safety summaries will be presented as appropriate. Further details will be specified in the', 'SAP.', 'Adverse events will be classified according to the MedDRA System Organ Class and Preferred', 'Term. Prior and concomitant medications will be classified according to the World Health', 'Organization (WHO) drug dictionary.', '8.2.9.', 'Other Analysis', 'Antidrug antibody results will be summarized descriptively.', '8.2.10.', 'Interim Analysis', 'No interim analysis is planned.', '9.', 'STUDY ADMINISTRATION', '9.1.', 'Ethical and Regulatory Considerations', 'This study will be conducted in accordance with the protocol and with the following:', 'Consensus ethical principles derived from international guidelines including the', 'Declaration of Helsinki and Council for International Organizations of Medical Sciences', '(CIOMS) International Ethical Guidelines', 'Applicable ICH Good Clinical Practice (GCP) Guidelines', 'Applicable laws and regulations', '9.1.1.', 'Informed Consent Process', 'The Investigator or his/her representative will explain the nature of the study to the patient or', 'his/her legally authorized representative (defined as an individual or juridical or other body', \"authorized under applicable law to consent, on behalf of a prospective patient, to the patient's\", 'participation in the clinical trial) and answer all questions regarding the study.', 'Patients must be informed that their participation is voluntary. Patients or their legally', 'authorized representative will be required to sign a statement of informed consent that meets the', 'requirements of 21 CFR 50, local regulations, ICH guidelines, Health Insurance Portability and', 'Accountability Act (HIPAA) requirements, where applicable, and the IRB/IEC or study center.', 'The medical record must include a statement that written informed consent was obtained before', 'the patient was enrolled in the study and the date the written consent was obtained. The', 'authorized person obtaining the informed consent must also sign the ICF.', 'Patients must be re-consented to the most current version of the ICF(s) during their participation', 'in the study.', \"A copy of the ICF(s) must be provided to the patient or the patient's legally authorized\", 'representative.', 'Property of the Sanofi Group - strictly confidential', '70']\n\n###\n\n", "completion": "END"}